Edinburgh, United Kingdom; 19th March 2026
Fitabeo Therapeutics, a specialty pharmaceutical company developing life-saving medicines, announces expansion of IP real estate with the grant of patents in the US and the EU for SpherionexT®, a platform technology with the ability to combine and complex release one or more compounds on single-layered fast-dissolving thin films.
Alex Mullen, Co-Founder and Chief Scientific Officer of Fitabeo Therapeutics, commented, “At Fitabeo Therapeutics, we are challenging the status quo with how medicines are delivered and are extremely proud of our expanding IP real estate with the grant of patents for SpherionexT® in the US and EU recently.
Together with our technology partner, the University of Strathclyde, we are enhancing access to convenient and compliant medicines for equitable access across all age and income groups. We believe that, with the changing demographics, the thin-film drug delivery, currently valued at $6.4 billion, is poised for exponential growth with the expansion of capabilities and the need to provide non-invasive drug delivery. Our quest to enhance the capabilities of thin-film drug delivery will put us front and centre of this evolution.”
-ends-
Notes to editors.
For further information, please contact:
Communications Manager
corporate@fitabeo.com
About Fitabeo
Fitabeo Therapeutics is a specialty pharmaceutical company that develops and commercialises innovative medicines focusing on indications where existing treatments are inadequate for the target population to provide better health outcomes. It deploys ground-breaking technologies to develop medicines that enable patient autonomy, decentralise patient care, and provide superior health outcomes.